Drug record
What four public record sets show for dapagliflozin. Saved Nov 10, 2026.
| Shortage | Not on the FDA shortage list | Details |
|---|---|---|
| Pharmacy cost | $0.163 each for the lowest-cost generic | Details |
| Medicare Part D, 2024 | $5.49 billion | Details |
| FDA recall records | 1 | Details |
Whether the FDA lists this drug as in short supply.
The list changes daily, and it covers the national supply. A pharmacy near you can be out of a drug that is not listed, or have one that is. See today's status.
The national average price retail pharmacies pay to buy it (NADAC).
The lowest-cost generic on file is Dapagliflozin 5 Mg Tablet: pharmacies pay about $0.163 each, or $4.89 for 30.
| Product as surveyed | Type | Pharmacy pays | For 30 | Price since |
|---|---|---|---|---|
| DAPAGLIFLOZIN 10 MG TABLET | Generic | $0.184 per each | $5.53 | Oct 28, 2026 |
| DAPAGLIFLOZIN 5 MG TABLET | Generic | $0.163 per each | $4.89 | Oct 28, 2026 |
| FARXIGA 10 MG TABLET | Brand | $12.08 per each | $362.29 | Oct 21, 2026 |
| FARXIGA 5 MG TABLET | Brand | $12.07 per each | $362.24 | Oct 21, 2026 |
This is not your price. NADAC is the national average that retail pharmacies pay to buy the drug, from the Medicaid survey for the week of Nov 11, 2026. What you pay adds the pharmacy's markup and dispensing fee and depends on your insurance or any discount card. "For 30" is shown only for products priced per tablet or capsule. Brand prices here are before any rebates.
Medicare Part D spending by product, from the latest annual file (2024).
In 2024, Medicare Part D plans and their members paid $5.49 billion for the 2 products below. That is up 645% from $736.8 million in 2020.
| Product | 2024 spending | People | Per prescription | Per person, year | 2020 spending |
|---|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | $5.29 billion | 1,269,216 | $938.93 | $4,168.36 | $736.8 million |
| Dapagliflozin Dapagliflozin Propanediol | $201.9 million | 223,069 | $515.46 | $905.25 | — |
Spending is the gross amount paid at the pharmacy by Part D plans and patients, before manufacturer rebates, which can be large for brand drugs. The same person can use more than one product, so people are not added up across rows. A dash means the file suppresses a small number or has no figure for that year. Not counted here, combination products that contain it: Qtern.
Recalls reported to the FDA that name this drug.
The FDA has 1 recall record that name dapagliflozin in the product description (1 Class II).
xigduo XR (dapagliflozin/metformin HCl extended-release) tablets 5 mg/1000 mg 60 Tablets Rx only NDC 0310-6260-60 Manufactured for: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850
Reason: CGMP Deviations: Intermittent exposure to temperature excursion during storage.
A recall covers specific lots from one company, not every bottle of the drug. Records include combination products and compounded versions that name this ingredient. Class I is the most serious: use could cause serious harm. Class II may cause temporary or reversible harm. Class III is unlikely to cause harm. To check a bottle, match the lot number on the label. See the live list. Do not stop a medicine because of a recall without asking your pharmacist.
These are saved records as of Nov 10, 2026; the sources update daily to yearly. For current figures open the live report for dapagliflozin. This page is public-record information, not medical advice.